Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial

The Lancet Oncology

Volumn 16, Issue 13, 2015, Pages 1344-1354

  Bruix, Jordi ^a   Takayama, Tadatoshi ^b   Mazzaferro, Vincenzo ^c   Chau, Gar Yang ^d   Yang, Jiamei ^e   Kudo, Masatoshi ^f   Cai, Jianqiang ^g   Poon, Ronnie T ^h   Han, Kwang Hyub ⁱ   Tak, Won Young ^j   Lee, Han Chu ^k   Song, Tianqiang ^l   Roayaie, Sasan ^m   Bolondi, Luigi ⁿ   Lee, Kwan Sik ^o   Makuuchi, Masatoshi ^p   Souza, Fabricio ^q   Le Berre, Marie Aude ^r   Meinhardt, Gerold ^s   Llovet, Josep M ^a,t  

^a UNIVERSITY OF BARCELONA   (Spain)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e Eastern Hepatobiliary Hospital   (China)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g CANCER HOSPITAL   (China)

^h QUEEN MARY HOSPITAL   (Hong Kong)

ⁱ Yonsei University College of Medicine   (South Korea)

^j Kyungpook National University School of Medicine   (South Korea)

^k Asan Medical Center   (South Korea)

^l TIANJIN MEDICAL UNIVERSITY   (China)

^m LENOX HILL HOSPITAL   (United States)

ⁿ UNIVERSITY OF BOLOGNA   (Italy)

^o Yonsei University College of Medicine   (South Korea)

^p UNIVERSITY OF TOKYO   (Japan)

^q Bayer HealthCare Pharmaceuticals ^*  (Brazil)

^r BAYER PHARMA AG   (Germany)

^s BAYER CORPORATION   (United States)

^t MOUNT SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PLACEBO; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALOPECIA; ARTHRALGIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BRAIN HEMORRHAGE; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CAUSE OF DEATH; CHILD PUGH SCORE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DESQUAMATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; DYSPNEA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HAND FOOT SYNDROME; HEADACHE; HEART MUSCLE ISCHEMIA; HEPATITIS B; HUMAN; HYPERTENSION; INSOMNIA; INTENTION TO TREAT ANALYSIS; INTERACTIVE VOICE RESPONSE SYSTEM; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE FREE SURVIVAL; RHINOPHARYNGITIS; THROMBOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ASIA; AUSTRALIA; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; EUROPE; KAPLAN MEIER METHOD; LIVER NEOPLASMS; LIVER RESECTION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEW ZEALAND; NORTH AMERICA; PATHOLOGY; RISK FACTOR; SOUTH AMERICA; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIA; AUSTRALIA; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HEPATECTOMY; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEW ZEALAND; NIACINAMIDE; NORTH AMERICA; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RISK FACTORS; SOUTH AMERICA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84953865606     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00198-9     Document Type: Article

References (35)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A Global cancer statistics, 2012. CA Cancer J Clin 2015, 65:87-108.
3. Bruix J, Sherman M Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022. the American Association for the Study of Liver Diseases.
4. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012, 56:908-943. European Association for the Study of the Liver and the European Organisation for Research and Treatment of Cancer.
5. Gao J, Xie L, Yang WS, et al. Risk factors of hepatocellular carcinoma--current status and perspectives. Asian Pac J Cancer Prev 2012, 13:743-752.
6. Mazzaferro V, Lencioni R, Majno P Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation. Semin Liver Dis 2014, 34:415-426.
7. Lu LC, Cheng AL, Poon RTP Recent advances in the prevention of hepatocellular carcinoma recurrence. Semin Liver Dis 2014, 34:427-434.
8. Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V Liver cancer: Approaching a personalized care. J Hepatol 2015, 62(suppl):S144-S156.
9. Bruix J, Gores GJ, Mazzaferro V Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014, 63:844-855.
10. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010, 4:439-474.
11. Verslype C, Rosmorduc O, Rougier P Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(suppl 7):vii41-vii48. the ESMO Guidelines Working Group.
12. Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011, 29:339-364. the HCC Expert Panel of Japan Society of Hepatology.
13. Zhuang L, Zeng X, Yang Z, Meng Z Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One 2013, 8:e61361.
14. Okita K, Izumi N, Matsui O, et al. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol 2015, 50:191-202. the Peretinoin Study Group.
15. Yoshida H, Shiratori Y, Kudo M, et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology 2011, 54:532-540.
16. Liu CJ, Lee PH, Lin DY, et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 2009, 50:958-968.
17. Progen annual report Progen Pharmaceuticals, (accessed July 14, 2015). http://www.progen-pharma.com/UserFiles/files/Annual%20Report/2008%20Annual%20Report%20Final.pdf.
18. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
19. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390. the SHARP Investigators Study Group.
20. Llovet JM, Schwartz M, Mazzaferro V Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005, 25:181-200.
21. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
22. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008, 47:97-104.
23. Chan EY, Larson AM, Fix OK, et al. Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. Liver Transpl 2008, 14:956-965.
24. Tung-Ping Poon R, Fan ST, Wong J Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000, 232:10-24.
25. Schulz KF, Altman DG, Moher D CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010, 340:c332. the CONSORT Group.
26. Colombo M, Iavarone M Role of antiviral treatment for HCC prevention. Best Pract Res Clin Gastroenterol 2014, 28:771-781.
27. Hsu YC, Wu CY, Lin JT Hepatitis C virus infection, antiviral therapy, and risk of hepatocellular carcinoma. Semin Oncol 2015, 42:329-338.
28. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012, 57:821-829.
29. Bruix J, Cheng A-L, Meinhardt G, Nakajima K, DeSanctis Y, Llovet J. Retrospective pooled analysis of advanced HCC patients in SHARP and AP randomized clinical trials. International Liver Cancer Association annual meeting. Sept 4-6, 2015. Paris, France. 248.
30. Iavarone M, Cabibbo G, Piscaglia F, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011, 54:2055-2063. the SOFIA (SOraFenib Italian Assessment) study group.
31. Bolondi L, Craxi A, Trevisani F, et al. Refining sorafenib therapy: lessons from clinical practice. Future Oncol 2015, 11:449-465.
32. Lencioni R, Kudo M, Ye SL, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2014, 68:609-617.
33. Yang JD, Nakamura I, Roberts LR The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 2011, 21:35-43.
34. Welti J, Loges S, Dimmeler S, Carmeliet P Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 2013, 123:3190-3200.
35. Haas NB, Manola J, Uzzo RJ, et al. Initial results from ASSURE (E2805): adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. Proc Am Soc Clin Oncol 2015, 33(suppl 7). abstr 403.